{
    "2018-05-15": [
        [
            {
                "time": "2018-01-02",
                "original_text": "MEIP Gets Funded, PFNX Riding High, GNPX Turns Heads",
                "features": {
                    "keywords": [
                        "funded",
                        "riding high",
                        "turns heads"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-16",
                "original_text": "Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "buy",
                        "expand",
                        "cancer pipeline"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-16",
                "original_text": "Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for May 16, 2018",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "ex-dividend",
                        "scheduled"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-15",
                "original_text": "An Update on Teva’s Highly Anticipated Migraine Drug",
                "features": {
                    "keywords": [
                        "Teva",
                        "migraine drug",
                        "highly anticipated"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-10",
                "original_text": "Star Kleiner Perkins VC may be launching her own firm",
                "features": {
                    "keywords": [
                        "Kleiner Perkins",
                        "launching",
                        "firm"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "venture capital"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-25",
                "original_text": "An Overview of Valeant Pharmaceuticals’ Performance in 1Q18",
                "features": {
                    "keywords": [
                        "Valeant Pharmaceuticals",
                        "performance",
                        "1Q18"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-05-05",
                "original_text": "Eli Lilly's cluster-headache treatment passes phase 3 test",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "cluster-headache",
                        "phase 3",
                        "passes"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Galcanezumab",
                        "Phase 3",
                        "meets primary endpoint"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-15",
                "original_text": "Lilly's migraine drug meets main goal in cluster headache trial",
                "features": {
                    "keywords": [
                        "Lilly",
                        "migraine drug",
                        "main goal",
                        "trial"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-20",
                "original_text": "Eli Lilly: Galcanezumab Meets Primary Endpoint In Phase 3 Study - Quick Facts",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Galcanezumab",
                        "Phase 3",
                        "primary endpoint"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}